The occupational health nurse holds a flu vaccine clinic. This is an example of which level of prevention?

Choice A reason: Costs aren’t low; U.S. spends high with mixed health outcomes. This errors per public health data. It’s universally distinct, contradicting actual cost and health indicator trends.

Choice B reason: U.S. has the highest health costs globally, yet health indicators lag. This aligns with nursing knowledge. It’s universally recognized, distinctly accurate per current health economics.

Choice C reason: Health indicators aren’t tops despite high costs; this is false. This misaligns with public health facts. It’s universally distinct, errors in outcome assessment.

Choice D reason: Costs aren’t low, and outcomes aren’t solely poor due to cost. This errors per health data. It’s universally distinct, misrepresenting U.S. health care reality.

Choice A reason: HSV-2 isn’t typically life-threatening like HIV, though it can complicate immunocompromised cases. Gonorrhea, bacterial and treatable, poses less chronic risk. This overstates HSV-2’s severity, as it’s manageable with antivirals, not fatal, making it less accurate for comparison here biologically.

Choice B reason: HSV-2 treatment, like acyclovir, isn’t extremely expensive compared to gonorrhea’s antibiotics. Cost varies by access, but chronicity, not expense, drives its challenge. This overlooks the persistent nature of HSV-2 versus gonorrhea’s curability, misaligning with the core difficulty clinically and practically.

Choice C reason: HSV-2, a virus, is chronic and incurable, residing in nerve ganglia lifelong, causing recurrent sores. Gonorrhea, bacterial, resolves with antibiotics. This persistent, untreatable viral nature makes HSV-2 more challenging, aligning with its clinical management and patient impact distinctly and accurately.

Choice D reason: HSV-2 treatment suppresses outbreaks but doesn’t grant immunity; it’s chronic. Gonorrhea cures fully, preventing recurrence with treatment. This is false for HSV-2, as its latency in nerves ensures potential flare-ups, contrasting sharply with gonorrhea’s resolution biologically and clinically here.